dr kristaps paddock, patient portal

Who is Dr Paddack?

To work with our patients to identify and address the root cause of their illness, achieve optimal wellness, and prevent future disease through the use of natural medicines, delivered in a comfortable and engaging setting.

Why choose Dr Paddack for autoimmune conditions?

Dr. Paddock graduated from the Albany Medical College,Albany Medical College in 1977. He works in Gloversville, NY and 1 other location and specializes in Otolaryngology-Head and Neck Surgery and Sleep Medicine. Dr. Paddock is affiliated …

Where can I find Plotsky Medical Center?

What patients are saying. Patient ratings and commments. All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are …

Why choose Dr Paddack for CPAP treatment?

Our Mission: To work with our patients to identify and address the root cause of their illness, achieve optimal wellness, and prevent future disease through the use of natural medicines, delivered in a comfortable and engaging setting.

OVERVIEW

Dr. Paddock graduated from the Albany Medical College,Albany Medical College in 1977. He works in Gloversville, NY and 1 other location and specializes in Head and Neck Surgery, Otolaryngology and Sleep Medicine. Dr. Paddock is affiliated with Nathan Littauer Hospital and Saratoga Hospital.

INSURANCE PLANS ACCEPTED (53)

Please verify insurance information directly with your doctor’s office as it may change frequently.

What is Crohn's disease?

Background & Aims Crohn’s disease (CD) is a lifelong illness with substantial morbidity, although new therapies and treatment paradigms have been developed. We provide guidance for treatment of ambulatory patients with mild to severe active luminal CD. Methods We performed a systematic review to identify published studies of the management of CD. The quality of evidence and strength of recommendations were rated according to the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach. Statements were developed through an iterative online platform and then finalized and voted on by a group of specialists. Results The consensus includes 41 statements focused on 6 main drug classes: antibiotics, 5-aminosalicylate, corticosteroids, immunosuppressants, biologic therapies, and other therapies. The group suggested against the use of antibiotics or 5-aminosalicylate as induction or maintenance therapies. Corticosteroid therapies (including budesonide) can be used as induction, but not maintenance therapies. Among immunosuppressants, thiopurines should not be used for induction, but can be used for maintenance therapy for selected low-risk patients. Parenteral methotrexate was proposed for induction and maintenance therapy in patients with corticosteroid-dependent CD. Biologic agents, including tumor necrosis factor antagonists, vedolizumab, and ustekinumab, were recommended for patients failed by conventional induction therapies and as maintenance therapy. The consensus group was unable to clearly define the role of concomitant immunosuppressant therapies in initiation of treatment with a biologic agent. Conclusions Optimal management of CD requires careful patient assessment, acknowledgement of patient preferences, evidence-based use of existing therapies, and thorough assessment to define treatment success.

What is the role of the mucosal barrier?

The interaction between host and external environment mainly occurs in the gastrointestinal tract, where the mucosal barrier has a critical role in many physiologic functions ranging from digestion, absorption, and metabolism. This barrier allows the passage and absorption of nutrients, but at the same time, it must regulate the contact between luminal antigens and the immune system, confining undesirable products to the lumen. Diet is an important regulator of the mucosal barrier, and the cross-talk among dietary factors, the immune system, and microbiota is crucial for the modulation of intestinal permeability and for the maintenance of gastrointestinal tract (GI) homeostasis. In the present review, we will discuss the role of a number of dietary nutrients that have been proposed as regulators of inflammation and epithelial barrier function. We will also consider the metabolic function of the microbiota, which is capable of elaborating the diverse nutrients and synthesizing products of great interest. Better knowledge of the influence of dietary nutrients on inflammation and barrier function can be important for the future development of new therapeutic approaches for patients with mucosal barrier dysfunction, a critical factor in the pathogenesis of many GI and non-GI diseases.

What is AKG in piglets?

Alpha-ketoglutarate (AKG) is an important cellular metabolite that participates in energy production and amino acid metabolism. However, the protective effects and mechanism of AKG on mucosal lesions have not been well understood. This study was conducted to investigate the effects of dietary AKG supplementation on epithelial restitution in early-weaning piglets under Escherichia coli lipopolysaccharide (LPS) induction. A total of 32 weaned piglets were used in a 2 × 2 factorial design; the major factors were dietary treatment (basal diet or AKG diet) and inflammatory challenge (LPS or saline). The results showed that AKG supplementation improved the growth performance and intestinal morphology in the LPS-induced early-weaning piglets. Compared with the basal diet, the AKG diet remarkably decreased the concentration and mRNA expression of intestinal inflammatory cytokines (IL-1β, IL-6, and IL-12) in the LPS-induced piglets. Moreover, AKG administration upregulated the mRNA expression of nutrient-sensing transporters (GLUT-2, SGLT-1, PEPT-1, I-FABP2) in the small intestine of both saline- and LPS-treated piglets, and improved the distribution and expression of tight-junction genes andproteins (ZO-1, Occludin, Claudins, E-cadherin). Collectively, our findings indicate that AKG has the potential to alleviate intestinal inflammatory response and improve epithelial restitution and nutrientsensing ability under stress injury in early-weaning piglets, and it also provides an experimental basis for enteral use of AKG in swine production and clinical application to prevent intestinal epithelial damage.

Does curcuma longa help with Crohn's disease?

The medications commonly used are expensive and associated with multiple side effects. Curcuma longa exerts anti-inflammatory and antioxidant actions and has shown positive effects on CD and UC treatment, possibly due to the presence of curcuminoids. The objective of this review was to evaluate the role of curcuminoids in the treatment of IBD. A search for articles associating curcuminoids and CD and UC was performed using MEDLINE–PubMed. It has been found that curcumin can reduce oxidative stress and inhibit the migration of neutrophils and inducible nitric oxide synthase in the intestine. It may also improve micro and macroscopic lesions, prevent apoptosis of intestinal cells and also induce the restoration of the mitogen-activated protein kinase immune reaction. As the incidence of CD and UC is growing in many populations, there is an urgency to find an appropriate and accessible therapeutic approach to improve quality of life of patients. The use of curcumin is cheap, efficient and associated with no side effects, and may become an alternative to the IBD treatment.

What are the components of immunonutrition?

Immunonutrition as currently administered focuses on five components. arginine, glutamine, omega-3 fatty acids, nucleotides, and antioxidants, and there is a strong argument to include probiotics and prebiotics as immunonutrition. This chapter begins with a brief overview of these seven components and mechanistic rationales for why each is a potential immunomodulator. The chapter continues with a summary of the mixed clinical evidence for immunonutrition interventions in particular patient populations where it might benefit. The chapter concludes with a summary of current therapeutic guidelines with an eye to future developments.

Is a kind of chronic inflammation, which has increasing incidence and prevalence in recent years.

Inflammatory Bowel Disease (IBD) is a kind of chronic inflammation, which has increasing incidence and prevalence in recent years. IBD mainly divides into Crohn’s disease (CD) and ulcerative colitis (UC). It is hard to cure IBD completely, and novel therapies are urgently needed. Amino acids (AAs) and their metabolites are regarded as important nutrients for humans and animals and also play an important role in IBD amelioration. In the present study, the potential protective effects of AAs and their metabolites on IBD had been summarized with the objective to provide insights into IBD moderating using dietary AAs and their metabolites as a potential adjuvant therapy.

About Angela Paddack

Dr. Angela Paddack is originally from Dallas, Texas. She attended the University of Arkansas for Medical Sciences for her residency in Otolaryngology & Head and Neck Surgery. Following residency, she served on the faculty at the university, where her practice was focused on the treatment of sinonasal disorders.

Specialty Areas

Dr. Paddack is also offering cosmetic BOTOX® treatments to her patients. Contact her office for details.